Please login to the form below
heart failure
This page shows the latest heart failure news and features for those working in and with pharma, biotech and healthcare.
Novartis follows Pfizer and freezes US prices this year
Novartis’decision to keep pricing steady has been helped by a rosy set of second-quarter results, with recent launches Cosentyx (secukinumab) for psoriasis and heart failure therapy Entresto (sacubitril and
Latest news
-
J&J’s Invokana aces diabetic kidney disease trial, setting up filings
found it cut hospitalizations due to heart failure – but in the meantime has seen sales go into reverse.
-
J&J says real-world data finds no amputation risk for Invokana
AZ is still waiting for data read-outs from its cardiovascular outcomes study (due in 2019), but presented real-world evidence for a benefit on heart failure rates last year.
-
Orphan drugs dominate UK Prix Galien shortlist, medtech debuts
The most recent winner of the Innovative Product Award, at the 2016 UK Prix Galien, was Novartis’Entresto – the first new treatment for heart failure in 15 years.
-
Real-world data finds patients feel better on Entresto, says Novartis
In that context, improving patients’symptoms and QoL in a progressive disease such as heart failure is important, as is identifying when their health starts to deteriorate. ... s Jardiance (empagliflozin), as around a third of patients with heart
-
Pfizer drug gets speedy FDA review for rare heart failure complication
Pfizer drug gets speedy FDA review for rare heart failure complication. ... Transthyretin cardiomyopathy is a fatal and underdiagnosed condition associated with progressive heart failure, with no FDA-approved treatments, and tafamidis chalked up a
More from news
Approximately 34 fully matching, plus 226 partially matching documents found.
Latest Intelligence
-
No incentive for a cure
Type 1 diabetes, heart failure, HIV - all examples of diseases that have transitioned from fatal conditions to chronic diseases, thanks to the progress in modern medicine.
-
Can value-based healthcare take off and reach for the skies?
costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.
-
Deal Watch February 2017
Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
-
Deal Watch January 2017
1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.
-
A healthy challenge
All told, 50 million people in the EU are afflicted by conditions such as diabetes, congestive heart failure, chronic obstructive pulmonary disease and asthma, and in 2013 more than 1.2m
More from intelligence
Approximately 1 fully matching, plus 18 partially matching documents found.
Latest appointments
-
uniQure appoints chief executive officer
for congestive heart failure and Huntington's disease into the clinic.”.
-
Cardio3 BioSciences appoints Warren Sherman chief medical officer
Sherman has over 30 years' cardiology experience, with a focus on cell-based therapies for treating patients post-myocardial infarction and with heart failure.
-
Acorda appoints new CFO
pain and heart failure.
-
Cardioxyl appoints Novartis scientist as chief medical officer
Dr Foo was responsible for the establishment and execution of multiple programmes in heart failure and the cardiorenal space at Novartis and will use her experience to lead research at ... Her unique combination of both early- and late-stage
-
CytomX makes senior changes following Pfizer deal
Prior to this period at Affymax, Dr Polu was executive director, global development at Amgen, where he worked in the development of products in nephrology, diabetes and heart failure.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Case Study: Qualitative research with payers in low and middle income countries
Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
-
Senior Medical Writer
-
Salary is DOE
-
Systematic Review Lead- London
-
Negotiable
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
-
Account Manager
-
Negotiable
Subscribe to our email news alerts
- Moving annual total (MAT)
- AZ prepares to file COPD triple, taking on rival GSK
- J&J files ‘breakthrough’ bladder cancer drug in US
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Teva wins FDA OK for crucial migraine drug
- NHS wins legal fight with pharma over off-label Avastin
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Attigo (part of the Mednet Group)
We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
